Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.90 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.90 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.90 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL7779839 | 1.00 | TSHR (0.90) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL51070 | 1.00 | — | — | |
| Pyridine SCHEMBL51069 | 1.00 | TSHR (0.90) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL839151 | 1.00 | — | — | |
| Pyridine SCHEMBL7628539 | 1.00 | TSHR (0.90) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL3113408 | 1.00 | TSHR (0.90) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL45360 | 1.00 | — | — | |
| Pyridine SCHEMBL18059958 | 1.00 | TSHR (0.90) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL11442039 | 1.00 | TSHR (0.90) | TSHRNAPRTTDP1NOTUMSLC6A2 | |
| Pyridine SCHEMBL26624876 | 1.00 | TSHR (0.90) | TSHRNAPRTTDP1NOTUMSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119001078-A | Paraquat rapid detection method and detection box thereof | 深圳市绿诗源生物技术有限公司 | 2024-11-22 | — | — | CN | claimed |
| EP-3628745-B1 | SPECTRAL INTENSITY RATIO (SIR) ANALYSIS FOR RAPID LIVE MICROBIAL ENUMERATION | TACOUNT EXACT LTD (IL) | 2023-01-04 | — | — | EP | claimed |
| CN-111841644-B | Metal-organic complex immobilized phosphotungstic acid catalyst for synthesizing epoxy cyclohexane | 郑州大学 | 2022-10-28 | — | — | CN | claimed |
| US-10022462-B2 | Methods and apparatus for synthesizing imaging agents, and intermediates thereof | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-07-17 | — | — | US | claimed |
| CN-108251381-A | A kind of paraquat monoclonal antibody hybridoma cell strain and its application | 江南大学 | 2018-07-06 | — | — | CN | claimed |
| US-20170258947-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-14 | — | — | US | claimed |
| WO-2015188144-A2 | FLUORESCENCE METHOD FOR SENSING CHLORINATED DISACCHARIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-10 | — | — | WO | claimed |
| CN-103130712-A | Paraquat hapten, paraquat complete antigen and preparation method of paraquat hapten and paraquat complete antigen | INST HYGIENE & ENVIRONMETNAL MEDICINE ACADEMY MILITARY MEDICAL SCIENCES | 2013-06-05 | — | — | CN | claimed |
| EP-2534136-A2 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | Lantheus Medical Imaging, Inc. (US) | 2012-12-19 | — | — | EP | claimed |
| CN-102633876-A | Synthetic method and application of paraquat antigen | UNIV JIANGNAN | 2012-08-15 | — | — | CN | claimed |
| CN-101918618-B | Pyrophosphate-based bath for plating on tin alloy layers | ATOTECH DEUTSCHLAND GMBH (DE) | 2012-02-22 | — | — | CN | claimed |
| WO-2011097649-A2 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-08-11 | — | — | WO | claimed |
| CN-101918618-A | Pyrophosphate-based bath for plating on tin alloy layers | ATOTECH DEUTSCHLAND GMBH | 2010-12-15 | — | — | CN | claimed |
| CN-101041670-B | Compound for high resolution image display device | NTERA LTD | 2010-06-23 | — | — | CN | claimed |
| CN-101041670-A | Displays for high resolution images and methods for producing same | NTERA LTD (IE) | 2007-09-26 | — | — | CN | claimed |
| CN-1796371-A | Dicationic bis-hydrazone compound, dye composition comprising at least one such compound, implementation process therefor and uses thereof | OREAL (FR) | 2006-07-05 | — | — | CN | claimed |
| CN-1259316-C | Heterocyclic compounds for age-related and diabetic vascular system complications | TORRENTAU PHARMACEUTICAL LTD (IN) | 2006-06-14 | — | — | CN | claimed |
| CN-1571939-A | Display for high resolution images and method of producing the same | NTERA LTD (IE) | 2005-01-26 | — | — | CN | claimed |
| CN-1498217-A | Heterocyclic compounds for aging-related and diabetic vascular complications | ������˹ҩƷ��˾ | 2004-05-19 | — | — | CN | claimed |
| CN-85106125-A | Prepare solid-state, the method for the quaternary dipyridinylium salt complex of weeding | — | 1986-07-02 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022462-B2 | Methods and apparatus for synthesizing imaging agents, and intermediates thereof | TNNI3, FABP3, MPI | SLC6A2 682/4885SLC6A4 1034/4885SLC6A3 1700/4885 |
| US-20170258947-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | TNNI3, FABP3, MPI | SLC6A2 682/4885SLC6A4 1034/4885SLC6A3 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.